Pharmacological and Therapeutic Potential of Sharbat Banafsha in the Management of Asthma (Diq Al-Nafas): A Narrative Review
DOI:
https://doi.org/10.47070/ijapr.v14i7.4201Keywords:
Asthma, Diq al-nafas, Dama, Sharbat Banafsha, Viola odorata, Unani MedicineAbstract
Asthma (Ḍiq Al-Nafas) is a chronic inflammatory airway disease characterized by recurrent episodes of breathlessness and wheezing due to reversible airway obstruction. Globally, it affects millions, with a significant burden in India. While conventional therapies such as bronchodilators and corticosteroids are effective, their long-term use raises safety concerns, prompting exploration of alternative therapeutic systems. Objectives: This review aims to evaluate the pharmacological and therapeutic potential of Sharbat Banafsha, a classical Unani formulation, in the management of asthma based on traditional literature and modern scientific evidence. Methods: A narrative review approach was employed by analyzing classical Unani texts alongside contemporary pharmacological and clinical studies focusing on Viola odorata, the principal ingredient of Sharbat Banafsha. Results: Sharbat Banafsha exhibits multiple therapeutic properties, including expectorant, concoctive, and mild laxative effects. Pharmacological studies indicate that Viola odorata possesses anti-inflammatory, bronchodilator, and antimicrobial activities. Clinical observations suggest improvement in respiratory symptoms and lung function, supporting its traditional use in managing asthma. Conclusion: Sharbat Banafsha demonstrates promising therapeutic potential as a complementary approach in asthma management. Integrating traditional Unani formulations with modern medicine may enhance patient outcomes and provide safer long-term alternatives, particularly in the context of increasing antimicrobial resistance and chronic disease burden.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Ayurveda and Pharma Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

